CoChat

Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity

Open access
Catenacci, Daniel V.T. · 2015 · Molecular Oncology
Cited by 144

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

The promise of ‘personalized cancer care’ with therapies toward specific molecular aberrations has potential to improve outcomes. However, there is recognized heterogeneity within any given tumor‐type from patient to patient (inter‐patient heterogeneity), and within an individual (intra‐patient heterogeneity) as demonstrated by molecular evolution through space (primary tumor to metastasis) and time (after therapy). These issues have become hurdles to advancing cancer treatment outcomes with novel molecularly targeted agents. Classic trial design paradigms are challenged by heterogeneity, as they are unable to test targeted therapeutics against low frequency genomic ‘oncogenic driver’ aberrations with adequate power. Usual accrual difficulties to clinical trials are exacerbated by low frequencies of any given molecular driver. To address these challenges, there is need for innovative clinical trial designs and strategies implementing novel diagnostic biomarker technologies to account for inter‐patient molecular diversity and scarce tissue for analysis. Importantly, there is also need for pre‐defined treatment priority algorithms given numerous aberrations commonly observed within any one individual sample. Access to multiple available therapeutic agents simultaneously is crucial. Finally intra‐patient heterogeneity through time may be addressed by serial biomarker assessment at the time of tumor progression. This report discusses various ‘next‐generation’ biomarker‐driven trial designs and their potentials and limitations to tackle these recognized molecular heterogeneity challenges. Regulatory hurdles, with respect to drug and companion diagnostic development and approval, are considered. Focus is on the ‘Expansion Platform Design Types I and II’, the latter demonstrated with a first example, ‘PANGEA: Personalized Anti‐Neoplastics for Gastro‐Esophageal Adenocarcinoma’. Applying integral medium‐throughput genomic and proteomic assays along with a practical biomarker assessment and treatment algorithm, ‘PANGEA’ attempts to address the problem of heterogeneity towards successful implementation of molecularly targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2014.09.011

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 144

Metadata

Authors
Catenacci, D. V. T.
Venue
Molecular Oncology
Publisher
Wiley
Published
2014-10-18
Volume
9
Issue
5
Pages
967-996
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W1966643394
Cited by
144
References
24
FWCI
6.32
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. https://app.cochat.ai/papers/10.1016/j.molonc.2014.09.011
The paper
Catenacci, D. V. T. (2015). Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Molecular Oncology. https://doi.org/10.1016/j.molonc.2014.09.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.